Vincent S. LoPriore, Executive Chairman at Hepion Pharmaceuticals, Inc. (HEPA), bought 10,000,000 shares at $0.05 ($500K) on 2026-08-03, disclosed to the SEC on 2026-08-12.
Executive Chairman Vincent S. LoPriore purchased $400,000 of stock at $0.05, marking the largest insider purchase in the company's history. This significant capital commitment by top leadership suggests confidence in the company's future despite the current stock price.
The stock is currently trading at $0.3181, sitting exactly at its 52-week high and 0.03% above its 52-week low of $0.318. The stock has been relatively flat over the last 90 days with no percentage change recorded.
Insider cluster: The purchase is flagged as the largest ever, signaling a strong internal vote of confidence. Sector momentum: The industry buy percentage over the last 90 days is 6.6%, indicating a supportive environment for biotech stocks.
Short interest: The stock has a short interest of approximately 4.1% of the float, which could lead to volatility if the stock price rallies. Valuation: The company has a negative forward P/E of -0.0066, indicating potential profitability concerns.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.05 | 2,000,000 | $100K | 20.0% |
| 2 | $0.05 | 8,000,000 | $400K | 80.0% |
| Total | $0.05 avg | 10,000,000 | $500K | 100% |